Literature DB >> 3484937

HLA-B27 associated cross-reactive marker on the cells of New Zealand patients with ankylosing spondylitis.

L E McGuigan, A F Geczy, J K Prendergast, J P Edmonds, H H Hart, H V Bashir.   

Abstract

We have previously shown that antibodies raised in rabbits to certain enteric bacteria will specifically lyse, in a 51Cr release assay, the peripheral blood lymphocytes (PBL) of 80% of HLA-B27 positive patients with ankylosing spondylitis (B27+ AS+) but not the PBL of HLA-B27 positive normal controls (B27+ AS-). Other laboratories have been unable to reproduce these findings. This study was designed to ascertain whether this lack of reproducibility was due to a peculiarity of our B27+ AS+ patients or to technical difficulties in the complement mediated 51Cr release assay. We have shown in this blind study that the PBL of 16 out of 18 B27+ AS+ patients from a New Zealand population were lysed by our antisera but none of the PBL of 20 B27+ AS- normal controls were lysed. The phenomenon of 'cross reactivity' between certain enteric bacteria and B27+ AS+ PBL is not confined to the Sydney AS population.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484937      PMCID: PMC1001837          DOI: 10.1136/ard.45.2.144

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Evidence for a specific B27-associated cell surface marker on lymphocytes of patients with ankylosing spondylitis.

Authors:  K Seager; H V Bashir; A F Geczy; J Edmonds; A de Vere-Tyndall
Journal:  Nature       Date:  1979-01-04       Impact factor: 49.962

2.  Normal range of spinal mobility. An objective clinical study.

Authors:  J M Moll; V Wright
Journal:  Ann Rheum Dis       Date:  1971-07       Impact factor: 19.103

3.  Antiserum to Klebsiella K43 BTS 1 specifically lyses lymphocytes of HLA-B27-positive patients with ankylosing spondylitis from a London population.

Authors:  J R Archer; M M Stubbs; H L Currey; A F Geczy
Journal:  Lancet       Date:  1985-02-09       Impact factor: 79.321

4.  Absence of impaired lymphocyte transformation to Klebsiella spp. in ankylosing spondylitis.

Authors:  T D Kinsella; C Lanteigne; M J Fritzler; R M Lewkonia
Journal:  Ann Rheum Dis       Date:  1984-08       Impact factor: 19.103

5.  Klebsiella related antigens in ankylosing spondylitis.

Authors:  A D Beaulieu; F Rousseau; E Israël-Assayag; R Roy
Journal:  J Rheumatol       Date:  1983-02       Impact factor: 4.666

6.  Enteric bacteria and HLA-B27 associated cell surface modification in patients with seronegative spondarthritis.

Authors:  J Edmonds; A F Geczy; J S Sullivan; J K Prendergast; L I Upfold; H V Bashir
Journal:  Br J Rheumatol       Date:  1983-11

7.  Ankylosing spondylitis. A disease in search of microbes.

Authors:  T D Kinsella; M J Fritzler; D J McNeil
Journal:  J Rheumatol       Date:  1983-02       Impact factor: 4.666

8.  A factor(s) in Klebsiella culture filtrates specifically modifies an HLA-B27 associated cell-surface component.

Authors:  A F Geczy; K Alexander; H V Bashir; J Edmonds
Journal:  Nature       Date:  1980-02-21       Impact factor: 49.962

9.  Employment in ankylosing spondylitis.

Authors:  L E McGuigan; H H Hart; P J Gow; B L Kidd; R R Grigor; T E Moore
Journal:  Ann Rheum Dis       Date:  1984-08       Impact factor: 19.103

10.  Possible role of enteric organisms in the pathogenesis of ankylosing spondylitis and other seronegative arthropathies.

Authors:  J K Prendergast; J S Sullivan; A Geczy; L I Upfold; J P Edmonds; H V Bashir; E Reiss-Levy
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

  10 in total
  2 in total

1.  Ankylosing spondylitis, HLA-B27, and klebsiella.

Authors:  A F Geczy
Journal:  Ann Rheum Dis       Date:  1986-03       Impact factor: 19.103

2.  Cytotoxic T lymphocytes against disease-associated determinant(s) in ankylosing spondylitis.

Authors:  A F Geczy; L E McGuigan; J S Sullivan; J P Edmonds
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.